LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

Home・Akciju saraksts・Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Inc

Atvērts

SektorsVeselības aprūpe

46.85 0.67

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

46.1

Max

47.71

Galvenie mērījumi
By Trading Economics
Ienākumi	36M -2.3M
Pārdošana	-3.9M 208M
P/E Sektora vidējais	48.435 50.102
EPS	0.21
Peļņas marža	-1.104
Darbinieki	778
EBITDA	-72M 19M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+34.54% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 4. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-2.1M 2.8B
Iepriekšējā atvēršanas cena	46.18
Iepriekšējā slēgšanas cena	46.85

Ziņu noskaņojums

By Acuity

60%

40%

285 / 344 Rangs Healthcare

Supernus Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 28. maijs 22:47 UTC

Peļņas

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

2026. g. 28. maijs 20:45 UTC

Peļņas

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

2026. g. 28. maijs 23:43 UTC

Tirgus saruna

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

2026. g. 28. maijs 23:39 UTC

Tirgus saruna

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

2026. g. 28. maijs 23:31 UTC

Tirgus saruna

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

2026. g. 28. maijs 23:17 UTC

Tirgus saruna

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

2026. g. 28. maijs 23:02 UTC

Tirgus saruna

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

2026. g. 28. maijs 22:41 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 28. maijs 22:41 UTC

Tirgus saruna

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

2026. g. 28. maijs 22:37 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

M&A-Related Insurance Payments In North America Rise -- Market Talk

2026. g. 28. maijs 22:04 UTC

Iegādes, apvienošanās, pārņemšana

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

2026. g. 28. maijs 22:04 UTC

Iegādes, apvienošanās, pārņemšana

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

2026. g. 28. maijs 21:12 UTC

Peļņas

Iegādes, apvienošanās, pārņemšana

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

2026. g. 28. maijs 21:00 UTC

Peļņas

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

2026. g. 28. maijs 20:57 UTC

Peļņas

Dell Stock Soars on Blowout Earnings -- Barrons.com

2026. g. 28. maijs 20:55 UTC

Peļņas

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

2026. g. 28. maijs 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 28. maijs 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 28. maijs 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 28. maijs 20:48 UTC

Karstas akcijas

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

2026. g. 28. maijs 20:34 UTC

Peļņas

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

2026. g. 28. maijs 20:31 UTC

Peļņas

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

2026. g. 28. maijs 20:28 UTC

Peļņas

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

2026. g. 28. maijs 20:26 UTC

Peļņas

Dell Stock Soars on Blowout Earnings -- Barrons.com

2026. g. 28. maijs 20:20 UTC

Peļņas

Costco 3Q Membership Fees $1.37B

2026. g. 28. maijs 20:20 UTC

Peļņas

Costco 3Q Net Sales $69.15B

2026. g. 28. maijs 20:19 UTC

Peļņas

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

2026. g. 28. maijs 20:19 UTC

Peļņas

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

2026. g. 28. maijs 20:17 UTC

Peļņas

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

2026. g. 28. maijs 20:17 UTC

Peļņas

Costco 3Q Same-Store Sales Up 9.8% >COST

Salīdzinājums

Cenas izmaiņa

Supernus Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

34.54% augšup

Prognoze 12 mēnešiem

Vidējais 62.75 USD 34.54%

Augstākais 66 USD

Zemākais 55 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Supernus Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

4 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 4 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Supernus Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

285 / 344 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.